CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $181,696 | -10.4% | 4,003 | +10.8% | 0.26% | +11.8% |
| Q2 2023 | $202,834 | +23.9% | 3,613 | -0.2% | 0.23% | +19.9% |
| Q1 2023 | $163,733 | +22.4% | 3,620 | +10.0% | 0.19% | +17.2% |
| Q4 2022 | $133,739 | -22.7% | 3,290 | +24.5% | 0.16% | -13.3% |
| Q3 2022 | $173,000 | -1.7% | 2,642 | -8.8% | 0.19% | +5.6% |
| Q2 2022 | $176,000 | -3.3% | 2,898 | 0.0% | 0.18% | +60.4% |
| Q1 2022 | $182,000 | -17.3% | 2,898 | -0.1% | 0.11% | +13.3% |
| Q4 2021 | $220,000 | +243.8% | 2,902 | +406.5% | 0.10% | +326.1% |
| Q3 2021 | $64,000 | – | 573 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |